Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Unknown 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Lymphoid 2Head & Neck 2Gynecologic 2Gastrointestinal 2Breast 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Recurrence 1Multiple Myeloma 1

Interventions

Dexamethasone 315Bortezomib 166Lenalidomide 132pomalidomide 113daratumumab 96carfilzomib 69Cyclophosphamide 44Calcium Dobesilate 41belantamab mafodotin 32elotuzumab 31fludarabine 27ixazomib 24isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14Injections 12idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Influenza Vaccines × Plasma cell × Clear all
NCT04626752 2020-11-13

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Hebei Senlang Biotechnology Inc., Ltd.

Phase EARLY_PHASE1 Unknown
50 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡